Yongping H. Cui

Key Laboratory Of Cellular Physiology Of Shanxi Medical University
Taiyuan, 030001, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 74 publications

Structural Insights into Tanc1/2 Autoinhibition and Their Implications for NDD Pathogenesis.

Structural Insights into Tanc1/2 Autoinhibition and Their Implications for NDD Pathogenesis.

Journal: Journal of molecular biology
Published: February 15, 2026

TMEM184A promotes progression and drug resistance in colorectal cancer: a bioinformatics and clinical study.

TMEM184A promotes progression and drug resistance in colorectal cancer: a bioinformatics and clinical study.

Journal: Scientific reports
Published: January 15, 2026

ZNF750 loss defines an ESCC subtype with constitutive NF-κB activation and vulnerability to bortezomib.

ZNF750 loss defines an ESCC subtype with constitutive NF-κB activation and vulnerability to bortezomib.

Journal: Biochimica et biophysica acta. Molecular basis of disease
Published: November 16, 2025

IER3 Promotes Malignant Progression of Colorectal Cancer Through the NF-κB Pathway.

IER3 Promotes Malignant Progression of Colorectal Cancer Through the NF-κB Pathway.

Journal: International journal of genomics
Published: October 09, 2025

Calcium-modulated GJB6-GRHL3 positive feedback loop attenuates ESCC progression through AKT signaling pathway inhibition.

Calcium-modulated GJB6-GRHL3 positive feedback loop attenuates ESCC progression through AKT signaling pathway inhibition.

Journal: NPJ precision oncology
Published: August 06, 2025

Characterization of retrocopies in 663 individuals with esophageal squamous cell carcinoma.

Characterization of retrocopies in 663 individuals with esophageal squamous cell carcinoma.

Journal: iScience
Published: July 07, 2025

IRF2BPL transcriptionally regulates IGFBP2 to promote tumor progression and suppresses immune cell infiltration in esophageal squamous cell carcinoma.

IRF2BPL transcriptionally regulates IGFBP2 to promote tumor progression and suppresses immune cell infiltration in esophageal squamous cell carcinoma.

Journal: Oncogene
Published: April 01, 2025

The consensus molecular subtypes of esophageal squamous cell carcinoma.

The consensus molecular subtypes of esophageal squamous cell carcinoma.

Journal: Signal transduction and targeted therapy
Published: March 13, 2025

SETDB2 participates in iron metabolism in esophageal squamous cell carcinoma via H3K9me3-mediated TFRC silencing.

SETDB2 participates in iron metabolism in esophageal squamous cell carcinoma via H3K9me3-mediated TFRC silencing.

Journal: Biochemical pharmacology
Published: January 24, 2025

Evolutionary adaptation and asymmetric inheritance of polyploid giant cancer cells in esophageal squamous cell carcinoma.

Evolutionary adaptation and asymmetric inheritance of polyploid giant cancer cells in esophageal squamous cell carcinoma.

Journal: Cancer letters
Published: January 18, 2025

YTHDC1 negatively regulates UBE3A to influence RAD51 ubiquitination and inhibit apoptosis in colorectal cancer cells.

YTHDC1 negatively regulates UBE3A to influence RAD51 ubiquitination and inhibit apoptosis in colorectal cancer cells.

Journal: Scientific reports
Published: December 02, 2024

Multi-omics analysis reveals immunosuppression in oesophageal squamous cell carcinoma induced by creatine accumulation and HK3 deficiency.

Multi-omics analysis reveals immunosuppression in oesophageal squamous cell carcinoma induced by creatine accumulation and HK3 deficiency.

Journal: Genome medicine
Published: July 06, 2024
Showing 1-12 of 74

Last Updated: 09/26/2026